GlassScriptPhysician profile
Rickey Washington
NPI 1750372942
$3,849.13
in general payments reported to CMS, 2019-2025
23 companies · $757 in 2025
The $757 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $266 · 2021: $359 · 2022: $319 · 2023: $869 · 2024: $743 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.90 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $700.94 | 2019-2024 | Xarelto |
| Pfizer INC. | $541.47 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.69 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $336.44 | 2020-2024 | Rybelsus, Ozempic |
| Ucb, INC. | $307.16 | 2021-2025 | Briviact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.30 | 2019-2024 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $235.53 | 2019-2025 | |
| Abbvie INC. | $154.90 | 2021-2025 | |
| Genzyme Corporation | $124.14 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.52 | 2019-2023 | Eliquis |
| Mallinckrodt Hospital Products INC. | $96.75 | 2024-2025 | Terlivaz |
| Xeris Pharmaceuticals, INC. | $92.31 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $80.77 | 2019-2023 | Verquvo |
| Gilead Sciences, INC. | $77.96 | 2024-2025 | |
| Inari Medical, INC. | $76.68 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.59 | 2019-2024 | |
| Melinta Therapeutics, LLC | $38.01 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $20.28 | 2019 | |
| Cvrx, INC. | $19.55 | 2025 | Barostim Neo System |
| Nabriva Therapeutics, Plc | $19.35 | 2020 | |
| Allergan, INC. | $16.14 | 2020 | |
| Cmp Pharma, INC. | $14.41 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.24 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rickey Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.